Mitral Regurgitation - Valvular Heart Disease Guidelines

Valvular Heart Disease

ACC/AHA Valvular Heart Disease - Mitral Regurgitation GUIDELINES Apps brought to you charge courtesy of Guideline Central and Abbott Vascular.

Issue link: https://eguideline.guidelinecentral.com/i/362036

Contents of this Issue

Navigation

Page 39 of 59

Prosthetic Valves Table 29. Prosthetic Valve Choice Recommendations COR LOE e choice of valve intervention, that is, repair or replacement, as well as type of prosthetic heart valve, should be a shared decision-making process that accounts for the patient's values and preferences, with full disclosure of the indications for and risks of anticoagulant therapy and the potential need for and risk of reoperation. I C A bioprosthesis is recommended in patients of any age for whom anticoagulant therapy is contraindicated, cannot be managed appropriately, or is not desired. I C A mechanical prosthesis is reasonable for AVR or MVR in patients <60 y of age who do not have a contraindication to anticoagulation. IIa B A bioprosthesis is reasonable in patients >70 y of age. IIa B Either a bioprosthetic or mechanical valve is reasonable in patients between 60 and 70 y of age. IIa B Replacement of the aortic valve by a pulmonary autogra (the Ross procedure), when performed by an experienced surgeon, may be considered in young patients when VKA anticoagulation is contraindicated or undesirable. IIb C 38

Articles in this issue

view archives of Mitral Regurgitation - Valvular Heart Disease Guidelines - Valvular Heart Disease